Redmile Group, LLC

This profile gathers the share dealings of Redmile Group, LLC across 16 companies, led by IGM Biosciences, Inc., Augmedix, Inc. and ADC Therapeutics SA. The record holds 81 filings, for trades running from 29 September 2015 to 6 August 2026.

Both buying and selling appear: 18 purchases worth €25.0M, against 9 sales worth €17.9M. No amount is published for 8 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 32 share grants and 1 option exercise. In 2026 alone, the filings show 2 purchases and 6 sales.

Half of the purchases are above €1.9M and half below. On 3 out of 16 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 7 August 2026, reports a transaction in Attovia Therapeutics, Inc. The latest purchase dates back some time: it was published 71 days ago, on 7 August 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.